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Multiple cellular proteins interact with LEDGF/p75
through a conserved unstructured consensus motif
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Lens epithelium-derived growth factor (LEDGF/p75) is an epigenetic reader and attractive
therapeutic target involved in HIV integration and the development of mixed lineage
leukaemia (MLL1) fusion-driven leukaemia. Besides HIV integrase and the MLL1-menin
complex, LEDGF/p75 interacts with various cellular proteins via its integrase binding domain
(IBD). Here we present structural characterization of IBD interactions with transcriptional
repressor JPO2 and domesticated transposase PogZ, and show that the PogZ interaction
is nearly identical to the interaction of LEDGF/p75 with MLL1. The interaction with the IBD is
maintained by an intrinsically disordered IBD-binding motif (IBM) common to all known
cellular partners of LEDGF/p75. In addition, based on IBM conservation, we identify
and validate IWS1 as a novel LEDGF/p75 interaction partner. Our results also reveal how
HIV integrase efficiently displaces cellular binding partners from LEDGF/p75. Finally,
the similar binding modes of LEDGF/p75 interaction partners represent a new challenge for
the development of selective interaction inhibitors.
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L
ens epithelium-derived growth factor (LEDGF/p75) is an
epigenetic reader recognizing H3K36me3 histone marks
via its N-terminal PWWP domain1,2. Knockout of the
gene encoding LEDGF/p75 and its splice variant p52 (Psip1)
leads to perinatal mortality and severe homeotic skeletal
transformations reminiscent of those seen in mice with Hox
mutations3. LEDGF/p75 has been linked to Hox gene regulation
through its interaction with the mixed lineage leukaemia (MLL1)-
menin complex4. Recent work has revealed that LEDGF/p75 is
involved in DNA double-strand break (DSB) repair by the
homologous recombination repair pathway, through recruitment
of C-terminal binding protein interacting protein (CtIP) to
DNA DSB5. In addition, LEDGF/p52 has been associated with
splicing through its interaction with serine/arginine-rich splicing
factor 1 (SRSF1)1,5. Currently it is not clear whether the
previously proposed roles of LEDGF/p75 in apoptosis and
stress response, as well as its increased expression levels in
different cancer types, are related to one of these functions6–11.
The Mll gene encodes a histone methyltransferase that forms a
ternary complex with LEDGF/p75 and the tumour suppressor
menin (MEN1) and is frequently targeted by chromosomal
translocations (see ref. 12 for review). Balanced genetic
rearrangements result in the formation of new fusion proteins
linked to childhood and adult de novo acute leukaemias, as well as
therapy-related acute myeloid and lymphoblastic leukaemias. The
LEDGF/p75 binding portion of MLL1 is retained in C-terminal
fusions (MLLN-fusion), which enables tethering of the MLLN-
fusion complexes to MLL1 target genes, resulting in leukaemic
transformation. The LEDGF/p75-MLL1-menin complex has
been structurally characterized, but the published X-ray data
revealed only part of the ternary complex (PDB ID 3U88 (ref. 13)).
Recently, we and others identified a second menin-independent
MLL1 binding site on LEDGF/p75 (refs 14,15). Both interfaces were
shown to be important for MLL fusion-mediated transformation
and represent valuable novel therapeutic targets14,15.
In addition to its cellular function, LEDGF/p75 has been
extensively studied in the context of HIV-1 integration16. LEDGF/
p75 interacts with HIV integrase (IN) through its C-terminal
integrase binding domain (IBD, amino-acid residues 347–429),
which is absent in LEDGF/p52 (Fig. 1). This interaction targets
viral integration into transcriptionally active regions of the host
chromatin recognized by the LEDGF/p75 PWWP domain17–21.
The important role of LEDGF/p75 in lentiviral replication
triggered the development of small molecules that efficiently
block HIV-1 replication, referred to as LEDGINs that target the
LEDGF/p75-HIV IN interaction interface22–29. LEDGINs are
currently under early clinical development.
Since LEDGF/p75 contributes to optimal viral replication and
leukaemic transformation and has become a new potential
therapeutic target for drug development, it is crucial to study
its physiological interactions. In addition to HIV IN and
MLL1-menin, the LEDGF/p75 IBD also interacts with CDC7-
activator of S-phase kinase complex (CDC7-ASK), JPO2
(also known as R1, RAM2 and CDCA7L) and pogo transposable
element with zinc finger domain (PogZ)30–33. JPO2 is a
454-amino-acid protein that binds c-Myc via a leucine-zipper
motif (amino-acid residues 213–235, Fig. 1) and contributes to
c-Myc-mediated transformation in medulloblastoma34. It also
acts as a transcriptional repressor of monoamino oxidases A and
B by binding to promoter Sp1 elements35,36. PogZ is a
domesticated transposase containing a predicted DDE
domain at its C-terminus (residues 1,117–1,323; Fig. 1)31. This
domain is typically present in enzymes that catalyse DNA
cleavage followed by a strand transfer reaction. PogZ regulates the
Aurora B kinase through interaction with heterochromatin
protein 1, which is required for correct chromosome
segregation during mitosis37. Like the HIV pre-integration and
MLL1-menin complexes, JPO2 and PogZ are tethered to
chromatin by LEDGF/p75 (refs 30,31,33).
Despite intensive research focused on HIV IN and MLL1/
menin interactions with the LEDGF/p75 IBD, the interaction
mode of other physiological IBD-binding partners remained
enigmatic. In this work, we characterized the interaction
interfaces of both JPO2 and PogZ with the IBD revealing
an overlap with the regions responsible for interactions with HIV
IN and MLL1. Identification of a highly conserved consensus
IBD-binding motif (IBM), present in all validated cellular
IBD-interacting proteins, led to discovery of interacts-with-Spt6
(IWS1) as a novel binding partner. Moreover, our results show
that the HIV IN interaction site on the IBD overlaps with that of
PogZ, JPO2 and MLL1 but shows an alternative interaction mode
explaining why HIV IN can efficiently outcompete endogenous
interaction partners.
Results
JPO2 interacts with the IBD through a disordered region. To
characterize the interactions between the LEDGF/p75 IBD and
JPO2, we expressed recombinant protein fragments in E. coli.
A JPO2 construct encoding residues 1–130 (JPO21–130), including
the specific LEDGF/p75 interaction domain described earlier
(amino-acid residues 62–94 (ref. 33) or 77–98 (ref. 30)), was most
suitable for overexpression in E. coli (Fig. 1). The IBD construct
used in this study contains LEDGF/p75 residues 345–426. The
C-terminal boundary was optimized based on analysis of the
crystal structure of the IBD in complex with HIV-1 IN (PDB ID
2B4J38). Inclusion of residues N425 and M426 at the C-terminus
dramatically improved protein expression yields.
Initially, we characterized the structural features of JPO21–130
in the absence of the IBD. Several lines of evidence led us to
conclude that JPO21–130 is intrinsically disordered. In particular,
circular dichroism (CD) spectra obtained for the fragment
revealed the absence of regular secondary structure elements
(Fig. 2a). In addition, evaluation of the protein’s thermal
stability in various buffers using differential scanning fluorimetry
(DSF) indicated the absence of a hydrophobic core (Fig. 2b).
Interestingly, the fluorescence profile of the IBD-JPO21–130
complex suggested formation of a hydrophobic core
(Supplementary Fig. 1b). Finally, 1D 1H and two-dimensional
(2D) 15N/1H HSQC NMR spectra of JPO21–130 showed poor
dispersion of groups of signals that are usually well-dispersed in
structured globular proteins (Fig. 2c,d and Supplementary Fig. 2).
Our experimental results indicating the lack of a regular
JPO21–130 structure are in good agreement with bioinformatic
analysis of JPO2 (Supplementary Fig. 1e,f).
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Figure 1 | Domain organization of LEDGF/p75 and its cellular binding
partners JPO2 and PogZ. Regions covered by protein constructs used in
this work are represented by black bars. The Pro-Trp-Trp-Pro domain
(PWWP), IBD, nuclear localization signal and specific interaction domain
are indicated.
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The intrinsically disordered JPO21–130 fragment readily
interacted with the IBD, forming a stable complex that could
be isolated using size-exclusion chromatography (SEC;
Supplementary Fig. 1g). The low micromolar binding
affinity (Kd¼ 1.9±0.2 mM) of the complex was determined
using isothermal titration calorimetry (ITC; Fig. 2f).
Interestingly, the stoichiometry of the interaction was estimated
as two molecules of IBD per molecule of JPO21–130 (average
N¼ 1.9).
PogZ dimers form a stable complex with the IBD. The PogZ
fragment used in this study (294 C-terminal residues; PogZ1117–1410)
includes the predicted DDE domain, which was previously
identified as a region responsible for interaction with the IBD31
(Fig. 1). Domain boundaries were estimated based on secondary
structure predictions and sequence homology between the DDE
domain of PogZ and Mos1, a transposase with known crystal
structure (PDB ID 2F7T39). Biophysical characterization including
1H NMR and 2D 15N/1H HSQC NMR spectra (Fig. 2e and
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Figure 2 | Biophysical characterization of JPO21–130 and PogZ1117–1410. (a) CD spectra of JPO21–130 and PogZ1117–1410. (b) Fluorescence intensities of
JPO21–130 and PogZ1117–1410 during DSF experiments. Two curves corresponding to experimental duplicates are shown. (c–e) Heteronuclear correlation
NMR spectra obtained for the IBD (c), JPO21–130 (d) and PogZ1117–1410 (e). The unstructured character of JPO1–130 (d) is clearly exhibited by the poor
dispersion of its backbone amide signals compared with the well-dispersed signals of the structured constructs IBD (c) and the majority of PogZ1117–1410
signals (e). (f,g) ITC data obtained for the IBD-JPO21–130 and IBD-PogZ1117–1410 interactions, respectively. Upper graph: experimental data; lower graph:
fit (line) of the dilution-corrected integrated heats (full circles) from each injection of 60 mM JPO21–130 or 114 mM PogZ1117–1410. (h) Analytical SEC analysis
of PogZ1117–1410.
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Supplementary Fig. 2) suggested that PogZ1117–1410 adopts a well-
defined conformation, although the presence of an unstructured
region at the C-terminus (residues 1,373–1,410) was confirmed by
limited proteolysis (Supplementary Fig. 3a) and by the presence of
more than 30 backbone amide signals in the 2D 15N/1H HSQC
spectrum that are considerably sharper and less well-dispersed than
the majority of amide signals from the structured part of the
protein. The structured character of PogZ1117–1410 was further
supported by CD spectra and DSF measurements. In particular,
CD spectra revealed a substantial presence of a-helices and
b-structures (Fig. 2a) and DSF showed a fluorescence profile
typical for a folded protein with a hydrophobic core (Fig. 2b). In
addition, PogZ1117–1410 showed a significant increase in thermal
stability in the presence of Mg2þ , as evidenced by a titration
experiment monitored by DSF (Supplementary Fig. 3b). This is in
agreement with the known metal-binding properties of the
predicted DDE domain in PogZ. To assess the affinity of
PogZ1117–1410 for the IBD, we used ITC (Fig. 2g). PogZ1117–1410
binds the IBD with a Kd of 1.6±0.2mM and a 1:1 stoichiometry
(N¼ 0.94). Analytical SEC indicated that PogZ1117–1410 exists as a
dimer in solution (Fig. 2h). The retention volume of PogZ1117–1410
(Vr¼ 14.24ml) corresponded to a molecular weight of 64,600Da
according to the calibration trendline equation. This suggests
dimeric assembly of PogZ1117–1410 (theoretical molecular weight:
33,111Da). Moreover, upon IBD binding the amide group signals
from the structured regions of PogZ almost completely disappeared
from the triple-resonance three-dimensional (3D) NMR spectra, as
the 80 kDa assembly is over the detection limit of these experiments,
while only signals from the relatively flexible C-termini can be
observed in the spectra. Signals from these flexible regions are
proportionally less affected by the molecular weight increase upon
complex formation.
Together, these data suggest that PogZ1117–1410 forms a
structured dimer with disordered C-termini. As analytical
SEC indicated monomeric assembly of free IBD in
solution (Supplementary Fig. 3c) and dimeric assembly of free
PogZ1117–1410 (Fig. 2h), each PogZ dimer forms a complex with
two molecules of IBD.
Interaction interfaces for cellular partners on IBD overlap. We
employed NMR spectroscopy for detailed characterization of the
interactions of the IBD with JPO2 and PogZ. Overlays
of the 2D 15N/1H HSQC spectra obtained for free 15N-labelled
IBD and 15N-labelled IBD in complex with either JPO21–130 or
PogZ1117–1410 reveal significant shifts in the positions of backbone
amide signals in both complexes (Fig. 3a,b). To interpret the
changes in the IBD signal positions, we acquired essentially
complete sequence-specific backbone resonance assignment of
13C/15N-labelled IBD using a set of standard triple-resonance
NMR experiments. We assigned 95.4% of 1H, 15N, 13C0 and 13Ca/
b atoms of the IBD. Backbone amide signals (15N and 1H) were
assigned for all residues except for four amino acids (E345, M348,
Q410 and T417). There were no unassigned resolved spin systems
detected in the spectra.
Formation of the IBD-JPO21–130 and IBD-PogZ1117–1410
complexes was followed via chemical shift perturbations of IBD
backbone signals (1H, 15N and 13C0) induced by each binding
partner in the 3D HNCO spectra. The specific changes induced
by JPO21–130 and PogZ1117–1410 overlapped significantly and were
localized in two distinct regions in the IBD sequence (Fig. 3c).
In particular, binding of JPO21–130 induced substantial changes
in two regions of the IBD structure (residues I359–D369 and
K402–M413) including two adjacent, surface-exposed interhelical
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Figure 3 | Structural characterization of the interactions of the IBD with JPO21–130 or PogZ1117–1410. Comparison of the 2D
15N/1H HSQC spectra of free
(black) and partner-bound IBD (red/green). The red spectrum in panel (a) was obtained from the complex of 15N-labelled IBD with unlabelled JPO21–130;
the green spectrum in panel (b) was obtained from the complex of 15N-labelled IBD with unlabelled PogZ1117–1410. (c) IBD minimal chemical shift values
divided by corresponding s.d. for backbone resonances (15N, 13C0 and 1HN) calculated for both complexes (red: IBD-JPO21–130; green IBD-PogZ1117–1410).
a-helices of the IBD (a1–a5) are schematically illustrated. (d,e) Structural overview of specific changes induced in the positions of IBD backbone
resonances by either JPO21–130 (d) or PogZ1117–1410 (e). Residues with substantial chemical shifts are highlighted on the IBD crystal structure (PDB ID
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loops (Fig. 3d). In addition, we identified a subset of residues
within those two regions that showed the largest perturbations
(N361, L363, K364, D366, L368, D369, I403, R404 and V408).
These residues are most likely in direct contact with JPO21–130
(Fig. 3d). We found no evidence of structural changes induced by
the binding of JPO21–130 in other parts of the IBD. Similarly,
substantial changes in the positions of IBD backbone signals
induced by PogZ1117–1410 binding were localized in regions
spanning residues K360–D369 and K402–I412. The residues
most affected by PogZ1117–1410 binding (N361, L363, K364, L368,
D369, I403 and V408) were analogous to those contributing to
JPO21–130 binding (Fig. 3d). Highly similar results were obtained
previously for mapping of the IBD-MLL1 interaction14,
indicating that JPO2, PogZ and MLL1 share a common
interaction interface on IBD (Supplementary Fig. 3d).
A linear consensus motif mediates the interaction with IBD.
Detailed mapping of the IBD-binding epitopes of JPO2 and
PogZ was performed analogously to that of the IBD. Overlays of
the 2D 15N/1H HSQC NMR spectra obtained for free 15N-labelled
JPO21–130 and PogZ1117–1410 and those measured in complex with
IBD revealed significant shifts in the backbone amide signal
positions (Fig. 4a,b). Interestingly, the changes observed in the
PogZ1117–1410 spectrum were strictly limited to a subset of more
intensive signals expected to represent the flexible unstructured
C-terminal region of the protein. To gain further insight into the
topology of these specific changes, we carried out sequence-specific
backbone resonance assignment of 13C/15N-labelled JPO21–130 and
PogZ1117–1410 using a set of standard triple-resonance NMR
experiments. We assigned 94.4% of 1H, 15N, 13C0 and 13Ca/b
atoms of JPO21–130. For PogZ1117–1410, we were able to assign
essentially all 1H, 15N, 13C0 and 13Ca/b signals of an apparently
unstructured C-terminal region (residues 1,368–1,410) that was
significantly affected by IBD binding.
The effects of complex formation on individual amino-acid
residues of JPO21–130 and PogZ1117–1410 were quantified
as minimal chemical shift values in backbone resonances
(15N, 13C0 and 1HN) divided by corresponding s.d. (Fig. 4c,d).
In the highly overlapping spectra of the unstructured JPO21–130,
we were able to discern seven significantly affected residues (V27,
G28, F29, T66, G86, F87 and N93). In the case of PogZ1117–1410,
the most affected residues (F1397, Y1398, G1399, F1400 and
A1403) were recognized in a single stretch at the C-terminus.
Alignment of the sequences encompassing these residues with
the recently published IBD-interacting residues of MLL1 (residues
140–155)14 revealed a conserved consensus sequence ((E/D)-X-E-
X-F-X-G-F), which we refer to as the IBM (Fig. 4e). Interestingly,
JPO2 contains two of these motifs, IBM-1 (D22-F29) and IBM-2
(E80-F87), while both MLL1 (E144-F151) and PogZ (E1393-
F1400) contain only one. Two phenylalanine residues in the IBM
of MLL1 have been shown to play a key role in binding to LEDGF/
p75; residues F148 and F151 anchor a MLL1-derived peptide in
two hydrophobic pockets on the IBD surface in a model of the
MLL1/menin-IBD complex (Fig. 4f), and their mutation abrogates
the interaction with LEDGF/p75 (ref. 14).
We introduced a F1397A point mutation (PogZF1397A)
or a double F1397A/F1400A mutation (PogZF1397A/F1400A)
into recombinant maltose binding protein (MBP)-tagged
PogZ1117–1410 and evaluated the interactions of these mutants
with Flag-tagged LEDGF/p75 in an AlphaScreen assay (Fig. 4g).
These mutations abolished the interaction of the PogZ fragment
with LEDGF/p75.
Corresponding single and double mutations were introduced
in both IBMs of MBP-tagged JPO2 (IBM-1: JPO2F26A and
JPO2F26A/F29A; IBM-2: JPO2F84A and JPO2F84A/F87A) and analysed
for their interactions with Flag-LEDGF/p75 (Fig. 4h,i). Although
these mutations affected the interaction with Flag-LEDGF/p75,
they were not sufficient to fully disrupt it. This suggests that
both IBM-1 and IBM-2 contribute to the interaction of JPO2
with LEDGF/p75. Mutations of phenylalanines in both motifs
(JPO2F26A/F84A or JPO2F26A/F29A/F84A/F87A) fully abolished the
interaction of JPO2 with LEDGF/p75 (Fig. 4j). The fact
that mutation of phenylalanine residues in the IBM is sufficient
to abrogate the interaction is in agreement with previous data
obtained for MLL1 (ref. 14). The glycine at position seven in the
IBM is most likely conserved owing to its ability to reduce
steric hindrance. However, the reason for conservation of
the glutamic/aspartic acid residues in positions one and three is
less clear. An interaction between this part of the consensus
motif and the IBD was not detected in the NMR experiments
with JPO2, PogZ (Fig. 4) or MLL1 (ref. 14). To assess the
importance of these residues in LEDGF/p75 interactions, we
mutated them to alanines. While PogZE1393A/E1395A did not
interact with LEDGF/p75 (Fig. 4g), single IBM mutations in JPO2
(JPO2D22A/E24A or JPO2E80A/E82A) disrupted the interaction only
partially (Fig. 4h,i). Combining mutations in both IBMs of JPO2
(JPO2D22A/E24A/E80A/E82A) reduced the interaction further, sup-
porting the notion that both JPO2 IBMs can bind LEDGF/p75
(Fig. 4j). The introduced mutations and their effects on LEDGF/
p75 binding are summarized in Supplementary Table 1. Taken
together, these results establish the existence of an unstructured
conserved protein motif responsible for interaction with the
LEDGF/p75 IBD.
Structural validation of the consensus motif. To provide a more
detailed insight into the actual organization of the interaction
interface, initially mapped by backbone NMR signal
perturbations, we solved the solution structure of the
PogZ-derived peptide in complex with the IBD (PDB ID: 2n3a),
as a representative of the IBM. In particular, we determined the
solution structure of the PogZ-derived peptide (PogZ1389–1404) in
complex with the IBD using the previously published approach14.
Comprehensive backbone and side-chain resonance assignments
for the PogZ1389–1404 bound 13C/15N labelled LEDGF/p75 IBD
were obtained using established triple-resonance experiments and
for the bound unlabelled PogZ1389–1404 peptide using 13C/15N
filtered homonuclear total correlation spectroscopy and nuclear
Overhauser enhancement spectroscopy (NOESY) experiments.
The essentially complete 15N, 13C and 1H resonance assignments
allowed automated assignment of the nuclear Overhauser effects
(NOEs) identified in 3D 15N/1H NOESY-HSQC, 13C/1H HSQC-
NOESY and in 2D 13C/15N-filtered/edited NOESY spectra using
the protocol implemented in Cyana. This yielded unique
assignments for 94.9% (1878/1978) of the NOE peaks observed,
providing 1,018 non-redundant 1H–1H distance constraints,
including 35 intermolecular constraints (Fig. 4k). Forty
converged structures for the IBD-PogZ1389–1404 complex with
no distance violations 40.2 Å were obtained from 100 random
starting conformations using 1,156 NMR-derived structural
constraints (B13.6 constraints per restrained residue). The 29
lowest energy conformers were further refined in explicit
solvent in YASARA (Fig. 4l). Structural statistics for the final
water-refined set of structures are shown in Supplementary
Table 2.
Analogously to our recently published work on the MLL-
LEDGF/p75 interaction14, detailed analysis of the NOESY
data revealed that the interaction of PogZ1389–1404 with the
IBD is maintained mainly by the aromatic side chains of
two phenylalanine residues (F1397 and F1400) within the
linear IBM (Fig. 4m). As expected, the IBD adopts a well-defined
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conformation, while PogZ1389–1404 remains relatively unstructured.
PogZ1389–1404 is anchored between the two interhelical loops
of IBD (aa I359 to D369 and K402 to M413) via F1397 and F1400
in a similar manner as MLL1140–160, as illustrated by a comparison
of the structural data obtained for both complexes shown in
Fig. 4m.
IWS1 is a novel interacting partner of LEDGF/p75. Next, we
used the ScanProsite40 algorithm to identify additional proteins
containing the IBM sequence. In addition to MLL1, JPO2 and
PogZ, we found the motif in the known LEDGF/p75 interaction
partners MLL2 (ref. 41) and ASK (DBF4) from the CDC7-ASK
complex32. Moreover, IBM and IBM-like motifs were found in
the mediator complex subunit 1 (Med1; residues 891–898) and
IWS1 (residues 484–491; Fig. 5a,b). Three other IBM-containing
proteins: eukaryotic translation initiation factor 4H (eiF4H),
ATP-binding cassette transporter 1 (ABCA1) and retinitis
pigmentosa 1 protein (RP1) were excluded from further studies
based on their structures, extranuclear localization and
physiological roles.
IWS1 forms a complex with transcription elongation factor
SPT6 and the C-terminal domain (CTD) of the large subunit
of RNA polymerase II (RNAPII). This complex recruits
HYPB/Setd2 histone methyltransferase, which controls
H3K36me3 methylation, affecting co-transcriptional pre-mRNA
splicing and export42,43. Because LEDGF is linked to both
alternative splicing and interaction with H3K36me3, we chose to
experimentally investigate the interaction between LEDGF/p75
and IWS1.
We evaluated the binding of recombinant His-tagged
full-length IWS1 (His-IWS1) to various GST-tagged LEDGF
deletion mutants using AlphaScreen. His-IWS1 interacted
exclusively with LEDGF/p75 fragments containing the
IBD (full-length GST-LEDGF/p75, GST-LEDGF/p75325–530 and
GST-IBD; (Figs 1 and 5c). The interaction between IWS1 and
LEDGF/p75 was corroborated by results from a pull-down
experiment. GST-tagged LEDGF/p75, LEDGF/p52, PWWP or
IBD were immobilized on glutathione sepharose resin and
incubated with nuclear extracts of SupT1 cells. IWS1 could only
be pulled down by GST-LEDGF/p75 and GST-IBD (Fig. 5d).
To obtain additional insight into the IWS1-LEDGF/p75
interaction, we cloned, expressed and purified a fragment
of IWS1 containing the predicted IBM and encoding residues
352–548 (IWS1352–548; Fig. 5b). Fragment boundaries were based
on computational analyses including domain and repeat
profiling and secondary structure, disorder and hydrophobicity
predictions. These predictions indicated that IWS1 residues
1–550 are unstructured and contain a highly acidic Glu-rich
region (residues 83–509; Supplementary Fig. 4a,b). The un-
structured character of the fragment was verified experimentally
using CD spectroscopy, DSF and 1D 1H and 2D 15N/1H HSQC
NMR spectra (Fig. 5e, Supplementary Figs 2 and 4c,d). Under
optimal conditions (25mM Tris-HCl, pH 8.5, 150mM NaCl,
0.05% BME), the IBD-IWS1352–548 complex could readily be
isolated using analytical SEC (Supplementary Fig. 4d), and the
affinity of the interaction was determined using ITC (Fig. 5f). We
calculated a Kd value of 6.7±2.0 mM and a 1:1 binding
stoichiometry (N¼ 0.96).
We followed the formation of the IBD-IWS1352–548 complexes
via chemical shift perturbations of the IBD backbone signals
(1H, 15N, 13C0; Fig. 5g) in the 3D HNCO spectra, analogous to
our experiments with JPO21–130 and PogZ1117–1410. The
specific changes induced by IWS1352–548 were localized to
residues K360–D369, K402–V408, I412 and M413 of the IBD
and overlap with those found for JPO2, PogZ and MLL1 (Fig. 5h).
Overall, these experiments unambiguously confirm a novel IBM-
mediated interaction between IWS1 and the LEDGF/p75 IBD.
As published earlier, the binding of HIV-1 integrase, JPO2,
PogZ and MLL1 to LEDGF/p75 is mutually exclusive14,30,31. Our
NMR data confirmed that IWS1 also shares the same interface on
the IBD (Fig. 5g,h). Therefore, we evaluated the effect of HIV-1
integrase catalytic core domain (INCCD), JPO21–130, PogZ1117–1410
and MLL1123–160 titration on the LEDGF/p75-IWS1 interaction
in an AlphaScreen assay. As shown in Fig. 5i, untagged INCCD,
JPO21–130, PogZ1117–1410 and MLL1123–160 efficiently displaced
IWS1 from the LEDGF/p75-IWS1 complex. Apparent 50%
inhibitory concentrations (IC50) were: 46 nM for INCCD (95%
confidence interval (CI) (36; 59)), 184 nM for JPO21–130 (95% CI
(153; 221)), 209 nM for PogZ1117–1410 (95% CI (162; 269)) and
848 nM for MLL1123–160 (95% CI (612; 1,175)). As described
above, we obtained dissociation constants for the three studied
LEDGF/p75 binding partners (JPO21–130 1.6 mM, PogZ1117–1410
1.9 mM and IWS1352–548 6.7 mM) using ITC. The Kd of LEDGF—
IN and MLL1—LEDGF interactions were reported earlier and are
10.9 nM and 86.3 mM, respectively14,44. The Kd and IC50 values
follow the same trend with INCCD having higher affinity than the
physiological binding partners.
HIV IN, JPO2 and PogZ are known to co-localize with
LEDGF/p75 on the chromatin of the cell16,30,31,33. To investigate
potential LEDGF/p75-IWS1 co-localization, HeLa cells were
transfected with a Flag-tagged IWS1 (Flag-IWS1) expression
construct and stained for endogenous LEDGF/p75 and the Flag-
tag (Supplementary Fig. 5a). As shown before LEDGF/p75
displayed a dense fine speckled distribution in interphase cells
and remained attached to chromatin during mitosis. Flag-tagged
IWS1 also localized to the nucleus of the cell but showed a more
equal distribution compared with endogenous LEDGF/p75
(Supplementary Fig. 5a). Flag-IWS1 did not co-localize
extensively with LEDGF/p75 in the interphase and did not
bind mitotic chromatin. However, under the same conditions
Flag-tagged HIV IN and JPO2 did co-localize extensively with
Figure 4 | The IBD-binding epitopes of PogZ and JPO2 are formed by a linear consensus motif. (a,b) Comparison of the 2D 15N/1H HSQC spectra of the
free (black) and IBD-bound (red) 13C/15N-labelled JPO21–130 (a) and PogZ1117–1410 (b). (c,d) JPO21–130 (c) and PogZ1117–1410 (d) minimal chemical shift
values divided by the corresponding s.d. for backbone resonances (15N, 13C0 and 1HN) calculated for the IBD-JPO21–130 or IBD-PogZ1117–1410 complexes.
(e) Consensus IBM identified in LEDGF/p75 binding partners. (f) Model of the MLL1-menin-LEDGF/p75 ternary complex14. Menin is highlighted in orange,
the LEDGF/p75 IBD in grey and MLL1 in pink. Amino-acid residues corresponding to the consensus motif (E144, E146, F148 and F151) are represented as
sticks. (g) Mutations in the IBM of PogZ abolish the interaction with LEDGF/p75. Recombinant WT or mutant MBP-PogZ variants were titrated against
Flag-LEDGF/p75 in AlphaScreen experiments. (h–j) AlphaScreens assessing LEDGF/p75 binding to JPO2 constructs with mutations in the first (h), second
(i) or both IBMs (j). WT or mutant MBP-JPO2 variants were titrated against 200nM Flag-LEDGF/p75. Error bars in all AlphaScreens represent s.d.
calculated from three independent experiments, each performed in duplicate. (k) A region from the 2D 13C/15N-filtered/edited NOESY spectrum obtained
for the IBD-PogZ1389–1404 complex. The spectrum shows intermolecular NOE contacts between
13C/15N-labelled IBD and unlabelled PogZ1389–1404.
(l) Converged structures of IBD-PogZ1389–1404 complex as determined by NMR (PDB ID: 2n3a). F1397 and F1400 are depicted as red sticks. (m) Detailed
view of the IBD-PogZ1389–1404 binding interface (PDB ID: 2n3a) in comparison with the one of MLL140–160 (PDB ID: 2msr
14). Representative NMR structures
are shown.
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LEDGF/p75 (Supplementary Fig. 6a) consistently with previously
published results16,30,31,33. Neither overexpression of eGFP-
LEDGF/p75 (Supplementary Fig. 7), or stable knockdown of
LEDGF/p75 (95% as determined by Q-RT-PCR; Supplementary
Fig. 5a) did alter the cellular distribution of Flag-IWS1. This is in
contrast to earlier reports on the LEDGF/p75 interactors JPO2
and HIV IN30,33,45.
During the reviewing process of this manuscript Ge´rard et al.,
reported on the interaction between LEDGF/p75 and IWS1 and
revealed its role in HIV latency46. IWS1 is known to form a stable
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complex with the Suppressor of Ty6 (Spt6) and Gerard et al.
could confirm the presence of a LEDGF/p75-IWS1-Spt6 triple
complex. We confirmed a direct interaction between recombinant
His-tagged IWS1 (His-IWS1) and a GST-tagged Spt6 fragment
(GST-Spt6194–230) in the absence of LEDGF/p75 in an
AlphaScreen assay (Supplementary Fig. 5b)47. In addition, we
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Figure 5 | LEDGF/p75 interacts with IWS1. (a) Alignment of the IBM and IBM-like motifs identified in human nuclear proteins. Conserved positions are
numbered. (b) Domain organization of IWS1. The IWS1352–548 fragment is highlighted by a black bar below the scheme. The transcription elongation factor
S-II domain, the nuclear localization signal5 and the IBM are indicated. (c) IWS1 interacts exclusively with LEDGF/p75 constructs containing the IBD.
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were analysed by Coomassie staining. IWS1 was detected by western blot using anti-IWS1 antibody. (e) 2D 15N/1H HSQC NMR spectra obtained for
IWS1352–548. The unstructured character of IWS1352–548 is illustrated by the poor dispersion of amide signals. (f) ITC data obtained for the IBD-IWS1352–548
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IWS1352–548. (g,h) Characterization of the IBD-IWS1352–548 interaction. (g) Comparison of the 2D
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15N-labelled IBD. (h) Minimal chemical shift values divided by the corresponding s.d. for IBD backbone resonances (15N, 13C0
and 1HN) calculated for the IBD-IWS1352–548 complex. (i) HIV-1 INCCD, JPO21–130, PogZ1117–1410 and MLL1123–160 protein fragments interfere with LEDGF/
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an AlphaScreen assay, while an increasing amount of untagged INCCD, JPO21–130, PogZ1117–1410 or MLL1123–160 protein fragments were added. Error bars
represent s.d. calculated from two independent experiments performed in duplicate.
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could observe extensive co-localization between HA-tagged IWS1
and Flag-Spt6 (Supplementary Fig. 6b). Direct interaction
between LEDGF/p75 and SPT6 could not be detected by
AlphaScreen or pull-down experiments. However, these
experiments confirmed the existence of the LEDGF/p75-IWS1-
Spt6 ternary complex (Supplementary Fig. 5c,d). Co-expression
of Spt6 did not increase the co-localization of Flag-IWS1 with
eGFP-LEDGF/p75 in HeLa cells (Supplementary Fig. 6c).
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The IBD-IBM interaction is mimicked by lentiviral integrases.
Our structural analysis revealed that MLL1, JPO2 and PogZ
interact with the same binding site on the IBD through their
IBMs. This binding site is formed mainly by residues from two
adjacent interhelical loops connecting IBD helices a1-a2 and
a4-a5. The actual binding site consists of a basic surface created
by positively charged residues (R404, R405, K407; Fig. 6a) and
two hydrophobic pockets (I359, K360, L363, L368, T399, K402,
I403, F406, K407 and V408). These hydrophobic pockets are
occupied by the conserved IBM phenylalanines, represented by
MLL1 F148 and F151 (Fig. 6b). Electrostatic complementarity
between the basic patch on the IBD and acidic residues of the
IBM, represented by E144 and E146 of MLL1, further contributes
to binding (Fig. 6a).
Structural comparison of the complexes of the IBD with the
IBM of MLL1 (ref. 14) or HIV-2 IN48 shows considerable overlap
of both parts of the interface (Fig. 6a,b). One of the hydrophobic
pockets on the IBD surface is occupied by W131 from the HIV-2
INCCD (Fig. 6b). The basic surface of LEDGF/75 is recognized by
the IN N-terminal domain (NTD). Specifically, acidic residues E6,
E10, and E13 from the a1 helix of the HIV-2 IN NTD face
positively charged residues K401, K402, R404 and R405 on the
IBD a4 helix (Fig. 6b). The IN NTD-LEDGF/p75 interface is
necessary for lentiviral integration48. In particular, LEDGF/p75
residues K401, R404 and R405 have a crucial role in HIV
infectivity48. Their counterparts, corresponding to E10 and E13 of
HIV-2 IN, are conserved among all lentiviral integrases (Fig. 6c).
To further confirm the overlap of the IBD-binding interfaces of
HIV-1 IN and other LEDGF/p75 interaction partners, we tested
the binding of LEDGF/p75 mutants defective for interaction with
MLL1 (ref. 14) to IWS1, PogZ1117–1410 or HIV-1 IN. These
mutations included L368A, which was expected to disrupt the
hydrophobic interactions with the IBM phenylalanines or HIV IN
tryptophan. R404D, R405D and K407D mutations were designed
to target the electrostatic interactions. As expected, the L368A
LEDGF/p75 mutant displayed reduced interactions with all
binding partners (Fig. 6). A similar effect was seen for LEDGF/
p75 containing the R404D/R405D double mutation, which is
known to affect interaction with HIV-2 IN E10 (Fig. 6). These
results underline the importance of these residues for LEDGF/p75
binding to many interaction partners and confirm features of the
overlapping interface. On the other hand, LEDGF/p75 K407
contacts negatively charged side chains of MLL1 but does not
establish contact with HIV IN14. Indeed, introduction of a K407D
mutation negatively affected the interaction of LEDGF/p75 with
IWS1 and PogZ1117–1410 but increased its binding to HIV-1
IN (Fig. 6). In addition, the K407D mutation slightly increased
the effect of the L386A mutation on His-IWS1 and MBP-
PogZ1117–1410 binding (Fig. 6). The PogZ and IWS1 IBMs thus
exhibit similar properties as the MLL1 IBM in binding to LEDGF/
p75 L368A and K407D14. In conclusion, although the binding
mode of HIV IN to the IBD is not identical to that of the cellular
binding partners, it uses the same basic surface and one of the
hydrophobic pockets.
Discussion
LEDGF/p75 is a highly conserved protein present in all vertebrates.
In addition, a protein harbouring PWWP and IBD-like domains
can be found in arthropods and nematodes such as Drosophila
melanogaster and Caenorhabditis elegans49. This conservation,
together with the perinatal mortality observed in Psip1 knockout
mice proves a crucial physiological role for LEDGF/p75 (ref. 3).
LEDGF/p75 is tethered to chromatin through its AT-hooks and
the PWWP domain, which recognizes H3K36me3 histone marks
(Fig. 1)1,50,51. Although LEDGF/p75-dependent chromatin
tethering is essential for MLL1 fusion-driven leukaemia and HIV
integration, a direct link to H3K36me3 marks has not yet been
established. Likewise, the link between H3K36me3 marks and the
potential cellular roles of LEDGF/p75 in DNA damage repair and
pre-mRNA processing is not clear.
Along with the PWWP domain, the IBD has a key role in the
known physiological and pathological functions of LEDGF/p75
by mediating its interactions with various cellular and
viral proteins30–32,52. Before this work, the interactions of a
diverse set of proteins with the IBD were not fully understood,
despite their importance to the development of therapies
targeting LEDGF/p75 interactions to block MLL fusion-
mediated leukaemic transformation and HIV integration53,54.
Our results revealed that JPO2 and PogZ interact with the IBD
through an intrinsically unstructured motif also found in MLL1
(ref. 14). Fragments of JPO2 and PogZ formed stable complexes
with the IBD with affinities in the low micromolar
range (1.6–1.9 mM) as measured by ITC. NMR experiments
revealed that the IBD interaction interfaces for JPO21–130 and
PogZ1117–1410 are almost identical to the menin-independent
MLL1 interface14. These interactions are maintained by two
phenylalanine side chains occupying two hydrophobic pockets on
the IBD. The first pocket is formed by IBD residues L363, L368,
I403, F406, K407 and V408, while the second is formed by I359,
K360, L363, T399, K402 and I403. Sequence alignment of the
IBD-interacting regions of JPO2, PogZ and MLL1 revealed a
consensus IBM ((E/D)-X-E-X-F-X-G-F), which was validated
through comprehensive mutational analysis. IBMs were also
identified in two other established LEDGF/p75 binding partners
(MLL2 and CDC7-ASK)32,52. The consensus motif harbours two
phenylalanine residues; the second phenylalanine is preceded by a
glycine, most likely to avoid steric hindrance. These features of
the IBM and its binding to IBD were validated by structural
analysis of a novel IBD-PogZ1389–1404 complex solution structure.
Direct comparison of the IBD-PogZ1389–1404 complex with the
structure obtained for the MLL1-derived peptide containing
the IBM (PDB ID: 2msr14) therefore validates the conservation of
the interactions mediated by the IBM (Fig. 4m). Several glutamic
and aspartic acid residues precede the F-X-G-F segment of the
motif. Although the interaction of these residues with IBD was
not directly detected in any of the PogZ, JPO2 or MLL1 NMR
experiments, mutagenesis experiments showed their complex-
stabilizing effect in AlphaScreen assays. Interestingly, the CDC7-
ASK IBM does not have a glutamic or aspartic acid residue at
position 3, but it contains a glutamic acid at position 4 (Fig. 5a).
In PogZ, the consensus motif was identified near the
C-terminus, spanning residues E1393-F1400 (Fig. 5a). Mutational
analysis confirmed that the phenylalanine residues are essential to
maintain the interaction with LEDGF/p75. Likewise, mutation of
both conserved glutamic acid residues to alanines abrogated the
interaction. While PogZ-like proteins can be found in all bilateria,
the IBM is apparently only present in bony vertebrates
(Supplementary Fig. 8). Surprisingly, JPO2 contains two IBMs
encoded by the second and third exon (Fig. 5a). The presence of
two IBMs is in agreement with results from our NMR and ITC
experiments, which show an IBD: JPO21–130 stoichiometry of 2:1.
Mutational analysis revealed that both motifs can interact with
full-length LEDGF/p75 and that phenylalanines from both IBMs
had to be mutated to abrogate the interaction. In contrast to
PogZ, simultaneous mutation of D22, E24, E80 and E82 to
alanines was not sufficient to fully abrogate the interaction. As the
IBM of PogZ does not contain neighbouring glutamic and
aspartic acid residues, E1394 and E1396 mutations have a more
dramatic effect on LEDGF/p75 binding. Like LEDGF/p75 and
PogZ, JPO2 is also evolutionally conserved among chordates. The
presence of both JPO2 IBM motifs, however, seems to be more
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variable. While most species contain two motifs, Xenopus
tropicalis and Gallus gallus have lost both motifs
(Supplementary Fig. 8). In each case, the absence of one or both
copies of the motif coincides with a loss of the N-terminal portion
of JPO2. Overall, the IBMs of LEDGF/p75 cellular interaction
partners are conserved among chordates, suggesting important
physiological roles for these interactions.
IBM represents a typical example of Short linear motif (SLiM),
a conserved amino-acid sequence present in natively disordered
parts of the proteins that mediate binding independently of a
larger sequence55. SLiMs are responsible for transient
protein–protein interactions and owing to their limited
intramolecular contacts with their partners, they tend to bind
with low affinity. The short length and the disordered character of
these regions provide a high level of plasticity, which makes
SLiMs suitable elements to tune the functions of various
eukaryotic regulatory proteins. On the other hand, such
features also allow SLiMs to be imitated by pathogenic
organisms. The ability to mimic the physiological interactions
carried out via SLiMs is one of the ways employed by pathogens
to take advantage of host cell functions and to guarantee
their replication56. HIV-1 integrase is one of numerous viral
proteins that evolved the ability to bind a cellular protein in a
similar way as its cellular binding partners and exploit its
physiological function.
PogZ1117–1410 forms dimers in solution as documented by
analytical SEC, similar to Mos-1 DNA transposase the closest
enzymatically active structural homologue of PogZ31. Together
with our ITC stoichiometry results, this suggests the presence of
two LEDGF/p75 molecules in the complex. Owing to the presence
of two IBMs in JPO2, the JPO2-LEDGF/p75 complex presumably
also contains two LEDGF/p75 molecules. A stable tetramer of HIV
IN also has been shown to associate with two molecules of LEDGF/
p75 (ref. 16). As such, it is tempting to speculate that multiple
LEDGF/p75 molecules are needed to form a functional complex. A
recent study reporting LEDGF/p75 dimers bound to certain DNA
topologies57 supports this hypothesis. In contrast, IWS1, MLL1
and CDC7-ASK dimers have not been described to date. However,
some MLL1 fusions induce dimerization of the fusion protein. For
these particular fusions, dimerization is required to maintain the
transformed state58.
In addition to the known LEDGF/p75 cellular interaction
partners, several other human proteins contain IBMs (IWS1,
Med1, eiF4H, ABCA1 and RP1). While the IBMs of Med1 and
IWS1 are unstructured, as determined by structural predictions
and NMR, respectively, the IBMs of other proteins are situated in
predicted structured regions. As all the IBMs known so far are
located in unstructured regions, we focused on the IWS1 protein.
Intrinsically disordered proteins lack 3D structure yet carry out
specific biological functions59. Typical intrinsically disordered
proteins provide a platform for transient complex interactions
between signalling and regulatory proteins. In eukaryotes, these
interactions are especially important in transcription and its
regulation59,60. IWS1 forms a stable complex with SPT6 and the
CTD of the large subunit of RNAPII42. In addition, IWS1 has
been shown to recruit HYPB/Setd2, the only histone
methyltransferase known to create H3K36me3 marks43. The
unstructured character of IWS1 was experimentally verified via
comprehensive biophysical characterization. Next, we confirmed
the interaction between IWS1 and LEDGF/p75 using various
experimental approaches including NMR, ITC, AlphaScreen and
pull-down assays. Moreover we showed that HIV-1 integrase,
JPO2, PogZ and MLL1 can compete with IWS1-LEDGF/p75
interaction. However, we did not see extensive co-localization of
LEDGF/p75 and IWS1 using confocal microscopy. In contrast to
JPO2 and HIV integrase, knockdown of LEDGF/p75 also did not
alter the IWS1 nuclear distribution. These results indicate that in
contrast to integrase and JPO2, other nuclear determinants are
dominant over LEDGF/p75 for the nuclear localization of
IWS1. In this regard it is known that IWS1 interacts with the
CTD of the large subunit of RNAPII complex through Spt6
(ref. 43). During the reviewing process of this manuscript, Ge´rard
et al. published an independent study, which confirmed the
existence of a LEDGF/p75-IWS1-Spt6 triple complex that was
suggested to have an important function during HIV latency46.
The existence of this complex was confirmed in our study.
When HIV enters the cell, integrase must compete with cellular
binding partners to interact with LEDGF/p75. While the high
affinity of HIV IN for LEDGF/p75 has been documented
previously44, our data provide a structure-based explanation. In
comparison with the cellular partners, binding to HIV IN buries a
considerably larger hydrophobic surface area. In addition to
increased solvent exclusion and concomitant larger entropy gain,
this larger interface also allows for additional electrostatic and van
der Waals interactions to be established. In addition, the binding
site on IN is structurally prearranged, in contrast to the
unstructured IBM.
Detailed characterization of LEDGF/p75 interaction interfaces
is important in light of efforts to develop novel inhibitors to target
IBD interactions with MLL1-menin or HIV-1 IN (reviewed in
ref. 61 and ref. 54). From our results, it is clear that potential
inhibitors targeting the LEDGF/p75 IBD might disturb other
physiological interactions. The cyclic peptide inhibitor CP65, for
example, has been shown to disrupt the interactions of LEDGF/
p75 with JPO2, MLL1 and HIV IN14,62. Although small cyclic
peptides bind to the IBD and can inhibit HIV replication and
leukaemic transformation in cell lines, their overexpression does
not lead to any apparent toxicity. On the other hand, highly
selective inhibitors of the HIV-1 IN-IBD interaction, such as
LEDGINs54, were developed by targeting the binding partner
(that is, HIV IN) rather than LEDGF/p75. However, this strategy
might be challenging to apply to the interaction of LEDGF/p75
with MLLN-fusions because the target would be intrinsically
unstructured.
In conclusion, our results unambiguously define a common
LEDGF/p75 interaction interface shared by JPO2, PogZ, MLL1,
IWS1 and HIV IN, which is most likely used by other known
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Figure 7 | Schematic representation of LEDGF/p75 IBD interactions.
LEDGF/p75 uses a common specific region in the IBD for interactions with
HIV IN and its cellular partners. Cellular binding partners interact with the
IBD via an unstructured consensus motif. JPO2, PogZ and lentiviral
integrase complexes can recruit more than one LEDGF/p75 molecule.
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LEDGF interaction partners (ASK and MLL2; Fig. 7). We
demonstrate that this part of the IBD serves as a recognition
interface for an intrinsically disordered consensus motif, whereby
LEDGF/p75 can act as a chromatin tethering factor for its binding
partners. Use of a single interface for several protein–protein
interactions with intrinsically disordered regions is analogous to
other transcription regulators such as the kinase-inducible
domain interacting (KIX) domain63. HIV has evolved an
alternative way to bind this recognition interface and usurp the
elegant molecular tethering mechanism of LEDGF/p75 to achieve
efficient integration.
Methods
Protein expression and purification. Unlabelled IBD, PogZ1117–1410, IWS1352–548
and JPO21–130 proteins were overexpressed from modified pMCSG7 vectors in
E. coli BL21 (DE3) cells grown at 30 C in lysogeny broth (LB) (Sigma) supple-
mented with 0.8% glycerol and 100 mgml 1 ampicillin. When cultures reached an
OD550 nm of B0.8, heterologous expression was induced by addition of isopropyl-
b-D-thiogalactopyranoside (IPTG). The IPTG concentration, duration and tem-
perature of cultivation were optimized for individual proteins to achieve maximal
protein yields. Optimal conditions were 0.25mM IPTG, 5 h at 30 C for JPO2;
0.2mM IPTG, 4 h at 20 C for the IBD; 0.25mM IPTG, 4 h at 30 C for PogZ1117–
1410 and 0.2mM IPTG, 4 h at 30 C for IWS1352–548.
Bacterial cells were collected by centrifugation and resuspended in lysis buffer.
The lysis buffer for the IBD, IWS1352–548 and PogZ1117–1410 was 25mM sodium
phosphate, pH 7.8, 1M NaCl, 40mM imidazole and 0.05% BME. For lysis of
JPO21–130, buffer containing 25mM sodium phosphate, pH 8.0, 1M NaCl, 15mM
imidazole and 0.05% BME was used. EDTA-free cOmplete protease inhibitor
cocktail (Roche) tablets were added to the cell suspensions to block protease
activity. Bacterial cells were disrupted by three passages through an Emulsiflex cell
disrupter at 30 ksi. The lysate was centrifuged to remove insoluble materials, and
the supernatant was used for further purification steps. The supernatant was
clarified by filtration through a sterile Millex filter unit (porosity 0.8 mm; Millipore)
and subjected to affinity chromatography using a HisTrap HP 5ml column (GE
Healthcare) equilibrated with lysis buffer. The His6-tagged protein was eluted in a
gradient of lysis buffer supplemented with 400mM imidazole, which was then
eliminated from the sample by dialysis against lysis buffer without imidazole. The
samples were incubated overnight with recombinant His6-tagged tobacco etch virus
(TEV) protease at 16 C to remove the affinity tag. Following TEV cleavage, a
second round of His-Select Nickel Affinity Gel affinity chromatography was
performed to remove TEV protease and uncleaved His6-tagged protein. The
sample was then concentrated using Amicon Ultra Concentrators (Millipore). The
final purification step was SEC on a Superdex 200 10/300 GL column using an A¨kta
Basic FPLC system (Amersham Biosciences) equilibrated in lysis buffer without
imidazole.
This purification protocol yielded 16.5mg of purified IBD and 7.1mg of
purified PogZ1117–1410 per liter of bacterial culture. The final yields of purified
JPO21–130 and IWS1352–548 were 5.1 and 9mg, respectively, per liter of bacterial
culture. The identities of purified JPO21–130 and IWS1352–548 were confirmed by
intact mass measurements (MALDI-TOF) and peptide mass fingerprinting
(LC–MS), as there were irregularities in their gel migration behaviour typical for
unstructured proteins (Supplementary Fig. 9).
Flag-tagged LEDGF/p75 and mutants were expressed and purified in the same
way as described for non-tagged LEDGF/p75 (ref. 30). Production of wild-type
(WT) MBP-JPO2 (ref. 45), MBP-PogZ1117–1410 (ref. 31) and mutants thereof were
performed as described earlier.
GST-tagged LEDGF/p75, LEDGF/p52, PWWP, IBD, GST-LEDGF/p75325–530
and GST-tagged Spt6194–230 were expressed in E. coli BL21 grown on LB medium
supplemented with 20mgml 1 ampicillin. Bacterial cultures were grown at 37 C.
Protein expression was induced with 1mM IPTG at an OD600 nm of 0.6. Cultures
were harvested after 4 h. Pellets were washed in 20ml STE buffer (10mM Tris-HCl,
pH 7.3, 100mM NaCl, 0.1mM EDTA), and stored at  20 C. Cells were lysed in
buffer containing 50mM Tris-HCl, pH 7.5, 250mM NaCl, 1mM dithiothreitol
(DTT), 0.1 mgml 1 DNAse (Thermo Scientific) and protease inhibitor (cOmplete,
EDTA-free, Roche). Purification was carried out by affinity chromatography on
Glutathione Sepharose-4 Fast Flow (GE Healthcare, Fairfield, CT, USA). The resin
was equilibrated with wash buffer (50mM Tris-HCl, pH 7.5, 250mM NaCl, 1mM
DTT), and GST-tagged proteins were eluted in wash buffer supplemented with
20mM glutathione. The fractions were analysed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) for protein content. Peak fractions
were pooled and dialysed against 50mM Tris-HCl, pH 7.5, 250mM NaCl and 10%
(v/v) glycerol.
Full-length His-IWS1 was expressed in E. coli BL21 (DE3) at 30 C. Protein
expression was induced with 0.2mM IPTG at an OD600 nm of 0.8, and the culture
was harvested after 3 h. Cells were washed in 20ml STE buffer (10mM Tris-HCl,
pH 7.5, 100mM NaCl, 0.1mM EDTA). Cell pellets were resuspended in lysis buffer
(50mM Tris-HCl, pH 7.5; 150mM NaCl, 20mM imidazole, 0.1 mgml 1 DNAse
(Thermo Scientific) and protease inhibitor (cOmplete, EDTA-free, Roche)) and
lysed by sonication. The lysate was cleared by centrifugation at 19,800g for 30min
at 4 C and subjected to affinity chromatography using His-Select Nickel Affinity
Gel (Sigma) equilibrated with wash buffer (50mM Tris-HCl, pH 7.5, 150mM
NaCl, 20mM imidazole). His-tagged proteins were eluted with wash buffer
containing 250mM imidazole. Fractions were analysed by SDS-PAGE for protein
content. Peak fractions were dialyzed against a 100-fold excess of 20mM Tris-HCl,
pH 7.5, 150mM NaCl, 10% (v/v) glycerol at 4 C overnight.
Uniformly 15N- and 15N/13C-labelled IBD, PogZ1117–1410 and JPO21–130 were
produced from cells grown in minimal media containing 15N-ammonium sulfate
and 13C-D-glucose as the sole nitrogen and carbon sources. The media were
supplemented with 20 mgml 1 ampicillin, and cells were grown at 30 C for 6 h
before being transferred to 20 C. After temperature stabilization, heterologous
expression was induced by addition of IPTG. The final concentration of IPTG for
both IBD and JPO21–130 expression was 0.2mM with cultivation for 15 h at 20 C;
for PogZ1117–1410 we used 0.2mM IPTG, 16 h at 20 C and for IWS1352–548 0.2mM
IPTG, 14 h at 18 C. The purification protocol for labelled proteins was the same as
for the corresponding recombinant protein fragments expressed by cells grown in
LB medium.
CD spectroscopy. Far-ultraviolet CD spectroscopy experiments were carried out
using a Jasco 815 spectrometer at 20 C. The buffer contained 10mM sodium
phosphate, pH 8.0, and 100mM NaCl, with final protein concentrations of
0.125mgml 1. The CD spectra were recorded from 190 to 300 nm in a 0.1 cm
quartz cell. After baseline correction, the spectra were converted to molar ellipticity
y (deg cm2 dmol 1) per residue, and the a-helical fractions were calculated.
Analytical SEC. Analytical SEC was performed using the A¨kta Basic FPLC system
(Amersham Biosciences) on a Superdex 200 10/300 GL Tricorn column (Phar-
macia). The column was equilibrated with buffer containing 50mM Tris-HCl,
pH 7.8, 150mM NaCl and 0.05% b-mercaptoethanol. The protein standards
(Sigma-Aldrich) used for molecular weight estimation were blue dextran
(2,000 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa),
cytochrome c (12.4 kDa) and aprotinin (6.5 kDa).
Differential scanning fluorimetry. DSF analysis using a real-time PCR Light-
Cycler 480 II (Roche) was performed to assess the stabilizing effects of various
buffers and their effects on complex formation. Sixteen buffers (100mM) covering
the near neutral pH range were tested in the presence or absence of 200mM NaCl
as described by Ericsson et al.64. Proteins (0.1mgml 1) were assayed in the
presence of 8 Sypro Orange dye (Invitrogen) in a total reaction volume of 25 ml.
The plates were sealed with LightCycler 480 Sealing Foil (Roche), and a
temperature gradient from 20 to 95 C with a rate of 1 Cmin 1 was applied.
The fluorescence intensity of Sypro Orange was recorded at 580 nm, with an
excitation wavelength of 465 nm. All experiments were performed at least in
duplicate.
Isothermal titration calorimetry. ITC experiments were performed using a
MicroCal Auto-iTC200 System (GE Healthcare) at 25 C. The samples were
prepared in 50mM Tris-HCl, pH 7.8, 150mM NaCl, 0.05% BME. Protein
concentrations were determined by amino-acid analysis. For the IBD-JPO21–130
complex, 2 ml aliquots of 60mM JPO21–130 were injected stepwise into a sample cell
containing 200 ml of 10mM IBD. For the IBD-PogZ1117–1410 complex, 2 ml aliquots
of 114mM PogZ1117–1410 were injected stepwise into a sample cell containing 200ml
of 10mM IBD. The samples for IWS1 titration experiments were prepared in
50mM Tris-HCl, pH 8.5, 150mM NaCl, 0.05% BME. For the IBD-IWS1352–548
complex, 2 ml aliquots of 145mM IWS1352–548 were injected stepwise into a sample
cell containing 200 ml of 15mM IBD. Each assay was accompanied by a control
experiment in which the binding buffer was titrated with the injected protein alone.
All experiments were performed at least in triplicate. The association constants and
stoichiometry (N) were estimated using MicroCal Origin software (GE Healthcare).
Known variances of each measurement were used to calculate the weighted average
of the dissociation constant (Kd) and stoichiometry as a maximum likelihood
estimator.
NMR spectroscopy. NMR spectra were acquired at 25 C on a 600MHz Bruker
Avance spectrometer equipped with triple-resonance (15N/13C/1H) cryoprobe. The
sample volume was 0.35ml, with protein concentrations ranging from 0.1mM to
0.35mM for free JPO21–130, IBD, IWS1352–548 and PogZ1117–1410 proteins as well as
IBD-JPO21–130, IBD-IWS1352–548 and IBD-PogZ1117–1410 complexes in 25mM
HEPES, pH 7.0, containing 100mM NaCl, 0.05% BME, 5% D2O/95% H2O. A
series of double- and triple-resonance spectra were recorded to determine
essentially complete sequence-specific resonance backbone assignments for the free
IBD and backbone and side-chain assignments for the PogZ1389–1404 bound IBD, as
previously described65,66. The specific interactions of PogZ1117–1410, IWS1352–548
or JPO21–130 with IBD were monitored by changes in the positions of signals of
15N/13C-labelled IBD in 3D HNCO spectra. From these changes, the most affected
amino-acid residues were determined using the minimal backbone chemical shift
(15N, 13C0 and 1HN) approach67. Amino-acid residues within these regions that
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were perturbed at least 1.5-fold the s.d. were then mapped on the structure of the
IBD in complex with HIV IN (PDB ID 2B4J38). The assignments for the bound
PogZ1389–1404 peptide were obtained using 13C/15N filtered homonuclear total
correlation spectroscopy and NOESY experiments. 1H–1H distance constraints
required to calculate the structure of the IBD-PogZ1389–1404 complex were
derived from 3D 15N/1H NOESY-HSQC, 13C/1H HSQC-NOESY and in 2D 13C/
15N-filtered/edited NOESY spectra, which were acquired using NOE mixing time
of 120ms. The family of converged structures for the IBD-PogZ1389–1404 complex
was initially calculated using Cyana 2.1. The combined automated NOE
assignment and structure determination protocol68 was used to automatically
assign the NOE cross-peaks identified in NOESY spectra and to produce
preliminary structures. In addition, backbone torsion angle constraints, generated
from assigned chemical shifts using the program TALOSþ 69 were included in the
calculations. Subsequently, five cycles of simulated annealing combined with
redundant dihedral angle constraints were used to produce the sets of converged
structures with no significant restraint violations (distance and van der Waals
violations o0.2 Å), which were further refined in explicit solvent in YASARA
(http://www.yasara.org/). Analysis and validation of the family of structures
obtained was carried out using the programs Molmol, iCING and PyMol.
Pull-down assays. A 40ml aliquot of 10 mM GST-LEDGF/p75, GST-LEDGF/
p75325–530, GST-IBD, GST-PWWP or GST-LEDGF/p52 was mixed with 40 ml
Glutathione Sepharose resin (GE Healthcare) pre-equilibrated with wash buffer
(50mM Tris-HCl, pH 7.3, 200mM NaCl) and incubated for 2 h at 4 C. The beads
were then washed five times with 600ml wash buffer. The presence of proteins
bound to the resin was confirmed by SDS-PAGE (Fig. 5d).
SupT1 cells (NIH: SupT1 from Dr James Hoxie) nuclear extracts were prepared
as described by Cherepanov et al.16. The cells were washed with PBS, harvested and
lysed with 700ml lysis buffer (50mM Tris/HCl, pH 7.3, 150mM NaCl, 0.5% (v/v)
Triton X-100, 10% glycerol, cOmplete protease inhibitor cocktail (Roche,
Germany)) for 10min on ice. The lysate was cleared by centrifugation to divide
nuclear and cytosolic fraction. To isolate the nuclear extract, the pellet was
resuspended in 50mM Tris/HCl, pH 7.3, 400mM NaCl, 0.5% (v/v) Triton X-100,
10% glycerol, cOmplete protease inhibitor cocktail (Roche, Germany) and
incubated for 30min on ice and subsequently cleared by centrifugation. Extracts
were diluted with 50mM Tris-HCl, pH 7.3, bringing the salt concentration down to
200mM. The lysate (1ml) was added to the GST-tagged proteins bound to
Glutathione Sepharose and incubated for 3 h at 4 C. The beads were collected by
centrifugation (60 s, 340g, 4 C) and washed five times in 600 ml lysis buffer. Bound
proteins were eluted with 50ml SDS-PAGE loading buffer and analysed by western
blotting for the presence of IWS1 using 1:5,000 anti-IWS1 polyclonal rabbit
antibody (Cell Signaling Technology, 5681S). Uncropped and marked scans of
western blot and SDS-PAGE gel are available in Supplementary information
(Supplementary Fig. 10).
AlphaScreen. AlphaScreen measurements were performed in a total volume of
25ml in 384-well Optiwell microtiter plates (PerkinElmer). The optimal protein
concentrations for each experiment were determined by cross-titration to avoid
binding curve perturbation while still yielding a high signal-to-noise ratio. All
components were diluted in assay buffer (25mM Tris-HCl, pH 7.4, 150mM NaCl,
1mM DTT, 0.1% (v/v) Tween-20 and 0.1% (w/v) bovine serum albumin). For
binding curve determinations, MBP-JPO2 and MBP-PogZ1117–1410 WT and/or
mutants were titrated against 200 nM Flag-LEDGF/p75. For identification of the
IWS1 interaction site on LEDGF, GST-LEDGF/p75, GST-LEDGF/p52, GST-
PWWP, GST-LEDGF/p75325–530 and GST-IBD were titrated against 20 nM His-
IWS1. To assess the interaction effects of LEDGF/p75 mutants, WT or mutant
LEDGF/p75 was titrated against 20 nM His-HIV-1 IN or His-IWS1 or 1 nM
MPB-PogZ or MBP-JPO2. Plates were incubated for 1 h at 4 C. Subsequently, a
mix of AlphaScreen donor and acceptor beads (PerkinElmer) was added (final
concentration 20mgml 1), bringing all proteins to the indicated final concentra-
tions. After 1 h of incubation at 20 C, the plate was analysed in an EnVision
Multi-label Reader in AlphaScreen mode (PerkinElmer). Each titration was per-
formed in duplicate, and assays were independently repeated three times. Results
were analysed in Prism 5.0 (GraphPad software) after non-linear regression with
the appropriate equations. One-site specific binding, taking ligand depletion into
account, was used for the apparent Kd measurements.
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